BioInvent And Immusol, Inc. To Collaborate On Antibody Therapeutic For Macular Degeneration
4/3/2006 5:23:03 PM
SAN DIEGO & LUND, Sweden--(BUSINESS WIRE)--April 3, 2006--BioInvent International AB (SAX:BINV) and Immusol, Inc. announced today a collaboration for the development of a fully human n-CoDeR® antibody for the treatment of age-related macular degeneration (AMD) and other ophthalmic disorders. Macular degeneration, a poorly treated condition, is the most common cause of vision loss in people over 60, affecting 20-25 million people worldwide. It is characterised by abnormal and uncontrolled vessel growth in the eye.
comments powered by